Analyst Mike Kratky of Leerink Partners reiterated a Buy rating on Boston Scientific, boosting the price target to $126.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mike Kratky’s rating is based on a combination of factors that point to a positive outlook for Boston Scientific. The company has shown strong execution of its growth strategy, particularly in its Electrophysiology (EP) and WATCHMAN segments, where it maintains a leading position with its FARAPULSE technology. This leadership is expected to continue with the anticipated launch of FARAPOINT in the second half of 2025 and the release of CHAMPION-AF data in the first half of 2026, which are seen as significant catalysts for growth.
Despite some challenges such as the removal of ACURATE and a substantial inventory charge in the second quarter of 2025, Boston Scientific has demonstrated strong financial performance. The company reported impressive sales growth, with notable increases in EP and WATCHMAN segments, and exceeded consensus expectations in several areas. Additionally, the company’s ability to achieve increased earnings per share guidance, despite higher R&D spending, reflects its operational leverage and potential for continued outperformance. These factors contribute to a favorable setup for the company’s stock in the near to medium term.
Kratky covers the Healthcare sector, focusing on stocks such as NeuroPace, Insulet, and Intuitive Surgical. According to TipRanks, Kratky has an average return of 8.5% and a 44.26% success rate on recommended stocks.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $125.00 price target.